Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome

CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

(2014) Hana Hájková et al.   Journal of Hematology & Oncology

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

(2013) Lisa Pleyer et al.   Journal of Hematology & Oncology

Signal transduction inhibitors in treatment of myelodysplastic syndromes

(2013) Lohith Bachegowda et al.   Journal of Hematology & Oncology

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

(2013) Lieke H van der Helm et al.   Journal of Hematology & Oncology

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

(2013) E H Estey   LEUKEMIA

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

(2013) Metin Karahoca et al.   Clinical Epigenetics

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update

(2012) Tina E. Joeckel et al.   SEMINARS IN HEMATOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

(2011) S Negrotto et al.   LEUKEMIA

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information

(2009) Johan E. Wallin et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity

(2009) Y. S. Chung et al.   BLOOD

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

(2009) Elias Jabbour et al.   CANCER

Decitabine in the treatment of myelodysplastic syndromes

(2009) Fabio PS Santos et al.   Expert Review of Anticancer Therapy

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical effectiveness of decitabine in severe sickle cell disease

(2008) Yogen Saunthararajah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evolution of decitabine development

(2008) Elias Jabbour et al.   CANCER

A tool for neutrophil guided dose adaptation in chemotherapy

(2008) Johan E. Wallin et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE